



SUVEN PHARMA

Earnings Presentation Q4 & FY23



Risk Statement


Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



Operation & Financial Performance Q4FY23




Businesswise data






Businesswise data






Financial Snapshot

Q4FY23* FY23




Key Ratios

Q4FY23* FY23



Financials Q4FY23




Note: Figures in INR Million

SUVEN


Financials FY23









Financials Q4FY23








Financials FY23







Financial Snapshot – Q4 and FY23


Financial Snapshot INR (Millions, except ratios and EPS) Quarter ended Year ended 31-Mar-23 31-Dec-22 31-Mar-22 31-Mar-23 31-Mar-22 Revenue from operations 3,643.90 3,484.89 3,638.47 13,300.80 13,202.22 107.55 125.11 1.343.96 445.52 1.877.88 Other Income 3,751.45 3,610.00 4,982.43 13,746.32 15,080.10 Total income EBITDA 1,853.83 1,595.78 2,919.65 6,276.30 7,677.76 **EBITDA Margin** 49.42% 44.20% 58.60% 45.66% 50.91% EBIT 1,747.55 7,286.79 1,486.64 2,815.44 5,847.85 EBIT Margin 46.58% 41.18% 56.51% 42.54% 48.32% 22.90 13.79 21.89 53.92 62.31 Finance costs Depreciation 106.27 109.14 104.21 428.45 390.97 423.04 378.18 548.90 1,467.91 1,643.49 Taxes 22.75% Taxes to PBT 24.53% 25.68% 19.65% 25.34% PAT (Standalone) 1,301.62 1,094.66 2,244.65 4,326.03 5,580.99 PAT Margin (Standalone) 34.70% 30.32% 45.05% 31.47% 37.01% Associate Company 411.12 -PAT (Consolidated) 1,239.71 1,077.21 916.68 4,112.90 4,538.05 PAT Margin (Consolidated) 33.05% 29.84% 18.40% 29.92% 30.09% EPS (Standalone) 5.11 4.30 8.82 16.99 21.92 **EPS** (Consolidated) 4.87 4.23 3.60 16.16 17.83 Paid up share capital (Re.1/sh) 254.57 254.56 254.56 254.56 254.57

All figures are in INR Million, other than ratios and EPS



Company Background





Brief Profile

BUSINESS OVERVIEW

 Integrated CDMO company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing.

KEY STRENGTHS

- Preferred global outsourcing partner with capabilities across the entire CDMO value chain.
- o Strong chemistry skills.

FINANCIAL OVERVIEW

- Standalone Revenues, EBIT and PAT of Rs 13476 Mn, Rs 5847 Mn and Rs 4326 Mn in FY23.
- Adjusted PBT for for FY23 stood at Rs. 5793.93 Mn compared to FY22 of Rs. 5716.29 Mn. The adjustment is related to inclusion of pre-tax dividend of Rs. 1508.19 Mn in other income.



Overview

Suven is an integrated Contract Development and Manufacturing Operations company

Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations.

Since our founding in 1989 (pre-demerger), Suven has established its core competency in cyanation and heterocyclic chemistry, including pyrimidines, quinolones, thiazoles, and imidazoles, in addition to demonstrating our proficiency in Carbohydrate and Chiral chemistry including tetrahydrofurans, amino acids and sulfoxides from gram to multi-ton scale.

Suven effectively uses its expanding infrastructure and ability to collaborate, from route scouting and development through commercial manufacture, to provide a consistent and reliable partner throughout a product's life cycle.

Suven is dedicated to going beyond commitment and delivering R&D and Manufacturing solutions, with flexibility, quality, speed, and cost effectiveness.




Our Focus

A full-fledged biopharmaceutical solutions provider for global pharmaceutical companies






Financial Approach




Business Drivers

Industry Relationship



Business Drivers

Execution Capabilities



Multi Location Facilities

Vizag, Andhra Pradesh, India





- o 307 KL reactor volumeo 3KL to 12KL Reactors
- o GL/SS (45No's)
- API's/Advanced Intermediate's/CMO







- o 120 kL reaction volume
- o 50L 6000 L GL/SS (45)
- o API Manufacturing
- o Formulation R&D

Banjara Hills, Hyderabad, India Corporate Office





- o Process Research
- o Discovery R&D, Analytical R&D
- o Killo lab, 30L CM Reactors (32)
- o 50L 4000 L GL/SS

Jeedimetla, Telangana, India R&D-Pilot Plant

- o 300 CM reactors (93)
- o 500L to 10 KL GL/SS
- o GMP Intermediates

Suryapet, Telangana, India Intermediate Mfg. Facility





- o Business Development
- Project Management
- Intellectual Property Management

USA, New Jersey Business Office



Contact

Suven Pharmaceuticals Ltd

8-2-334, SDE Serene Chambers, 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500 034, Telangana, INDIA.

+91-40-2354-9414 /1142 /3311

For queries and requests, please contact:

Sunder Venkatraman Suven Pharmaceuticals Ltd

Tel: +91 939 248 3011 Email: <u>info@suvenpharm.com</u> For more info: <u>www.suvenpharm.com</u>

Gavin Desa / Rishab Barar CDR - India

Tel: +91 22 6645 1237 / 1235 Email: gavin@cdr-india.com rishab@cdr-india.com

